Apexigen is a clinical-stage biopharmaceutical company discovering and developing innovative immuno-oncology therapeutics generated by APXiMAB™, the Company’s proprietary antibody drug discovery platform.

Register for Details

For more details on financing and valuation for Apexigen, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about Apexigen

Forge green plus iconForge green minus icon

What is Apexigen's IPO price?

Apexigen's IPO price is $0.3851 as of 8/22/23.
Forge green plus iconForge green minus icon

What is Apexigen's funding to date?

Apexigen has raised $165.38MM to date.
Forge green plus iconForge green minus icon

When was Apexigen founded?

Apexigen was founded in 2010.

Apexigen Funding Rounds and Last Known Valuation

Date Funding Round Funding Raised Price per Share Last Known Valuation
3/24/2020 Series C $127.86MM raised $XXX.XX $XXX.XX
8/8/2018 Series B $15MM raised $XXX.XX $XXX.XX
8/8/2013 Series A-1 and A-2 $22.52MM raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data
Updated on: Nov 15, 2023


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.